VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CVS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CVSCVS Health Corp.
$85.81$109.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCVSCash Flow

CVS Health Corp. (CVS) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow of $4.7B covered $853M of dividends in 2026Q3, but quarterly OCF swung from a $745M outflow in 2024Q3 to $6.3B in 2026Q2, indicating uneven float generation and reliance on operating cash for capital returns.

Income StatementBalance SheetCash FlowRatios

CVS Cash Flow Statement

Annual statement

CVS Cash Flow Statement

CVS Health Corp. (CVS) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations18.71B10.64B9.11B13.43B16.18B18.27B15.87B12.85B8.87B8.01B10.14B8.54B8.14B5.78B6.67B5.86B4.78B4.04B3.95B3.23B1.74B1.61B914.2M968.9M1.2B680.6M780.2M726.3M292.4M-105.8M327.2M
Operating CF Growth %803.46%16.82%-32.17%-17.01%-11.43%15.13%23.48%44.93%10.72%-21.04%18.76%4.94%40.71%-13.31%13.92%22.54%18.44%2.23%22.21%85.36%8.08%76.34%-5.65%-19.58%77.02%-12.77%7.42%148.39%376.37%-132.34%-28.87%
Operating CF / Revenue %4.45%2.65%2.44%3.75%5.02%6.25%5.9%5%4.56%4.33%5.71%5.57%5.84%4.56%5.42%5.47%4.99%4.11%4.51%4.23%3.98%4.36%2.99%3.64%4.98%3.06%3.88%4.01%1.91%-0.77%2.77%
Net Income11.05B1.73B4.59B8.37B4.33B7.99B7.19B6.63B-596M6.62B5.32B5.24B4.64B4.59B3.86B3.46B3.42B3.7B3.21B2.64B1.37B1.22B959.3M847.3M716.6M413.2M746M635.1M384.5M105.9M208.2M
Depreciation & Amortization4.52B4.61B4.6B4.37B4.22B4.49B4.44B4.37B2.72B2.48B2.48B2.09B1.93B1.87B1.75B1.57B1.47B1.39B1.27B1.09B733.3M589.1M439.9M341.7M310.3M320.8M296.6M277.9M249.7M242.6M262.8M
Stock-Based Compensation610M535M540M588M447M484M400M453M280M234M222M230M165M141M132M135M150M165M92M000000000000
Deferred Taxes198M102M-572M-676M-2.03B-402M-570M-654M87M-1.33B18M-252M-58M-86M-111M144M30M48M-3M40.1M98.2M13.5M-7.2M41.1M71.8M-83.5M43.8M124.8M80.6M-140.4M116.4M
Other Non-Cash Items-221M5.14B-153M765M2.39B1.85B1.24B548M6.49B421M778M-14M521M0348M-53M00078M69.9M0000352.5M00188.6M466.4M146.6M
Working Capital Changes2.54B-1.47B109M15M6.82B3.86B3.16B1.5B-112M-416M1.33B1.24B934M-734M687M604M-294M-1.26B-628M-620M-527.9M-215.2M-477.8M-261.2M106.1M-322.4M-306.2M-311.5M-611M-780.3M-406.8M
Cash from Investing-7.54B-5.87B-7.61B-20.89B-5.05B-5.26B-5.53B-3.34B-43.28B-2.88B-2.47B-13.42B-4.04B-1.83B-1.85B-2.41B-1.64B-1.07B-4.58B-3.08B-4.59B-911.6M-3.16B-753.6M-735.8M-536.8M-640.5M-566.4M-585.4M160.8M23.4M
Capital Expenditures-3.14B-2.83B-2.78B-3.03B-2.73B-2.52B-2.44B-2.46B-2.04B-1.92B-2.22B-2.37B-2.14B-1.98B-2.03B-1.87B-2B-2.55B-2.18B-1.81B-1.77B-1.5B-1.35B-1.12B-1.11B-713.6M-695.3M-722.7M-502.3M-341.6M-702.8M
Acquisitions-22M-436M-95M-16.61B-1.39B-146M-26M-444M-41.39B-1.18B-524M-11.47B-2.44B-415M-371M-1.19B-177M-101M-2.65B-1.98B-4.22B0-2.29B-133.1M-93.5M-159.1M-263.3M-101.1M-133.6M00
Purchase of Investments-17.56B-15.01B-15.19B-9.04B-7.75B-9.96B-9.64B-7.53B-692M-137M-80M-267M-157M-226M0-3M0-5M0000000000000
Sale/Maturity of Investments13.13B12.38B10.35B7.73B6.73B7.25B6.47B7.05B817M61M91M243M161M136M060M1M0232M0000000000309.7M485.8M
Other Investing54M26M101M68M85M122M101M47M21M298M267M446M526M654M552M596M541M1.58B19M706.9M1.4B583.8M478.1M501.2M466.5M335.9M318.1M257.4M50.5M192.7M240.4M
Cash from Financing-8.57B-4.94B-1.14B2.68B-10.52B-11.36B-7.7B-7.65B36.82B-6.75B-6.76B4.88B-5.69B-1.24B-4.86B-3.46B-2.8B-3.23B929M377.9M2.87B-579.4M1.8B-72.5M-4.9M-244.8M-32.4M-110.7M281.3M-369.3M-24.7M
Dividends Paid-3.42B-3.4B-3.37B-3.13B-2.91B-2.63B-2.62B-2.6B-2.04B-2.05B-1.84B-1.58B-1.29B-1.1B-829M-674M-479M-439M-383M-322.4M-140.9M-131.6M-119.8M-105.2M-104.9M-105.2M-104.8M-104.7M-102.5M-87.6M-137.5M
Share Repurchases00-3.02B-2.01B-3.5B0000-4.36B-4.46B-5B-4B-3.98B-4.33B-3B-1.5B-2.48B-23M-5.37B00000-129M-163.2M0000
Stock Issued425M394M0000000000000000327.8M552.4M187.6M178.4M129.8M38.3M34M47.3M97.8M20.4M121.1M169.1M128.5M
Debt Issuance (Net)-4M-1000K1000K1000K-1000K-1000K-1000K-1000K1000K-1000K-1000K1000K-1000K1000K-1000K-1000K-1000K-1000K1000K1000K1000K-1000K1000K-1000K1000K-1000K1000K-1000K1000K-1000K1000K
Other Financing-247M1.96B202M-105M102M536M601M269M592M257M154M238M527M562M838M424M308M266M381M97.8M42.6M000000000-25.8M
Net Change in Cash2.53B-172M359M-4.78B614M1.65B2.63B1.85B2.4B-1.62B912M-22M-1.61B2.71B-38M-14M341M-266M296M525.9M17.3M121.1M-450.9M142.8M464.1M-101M107.3M49.2M-11.7M-314.3M-180.9M
Exchange Rate Effect-62M0000000-4M1M2M-20M-6M3M00000000000000000
Cash at Beginning11.54B8.88B8.53B13.3B12.69B11.04B8.41B6.55B1.9B3.52B2.61B2.48B4.09B1.38B1.41B1.43B1.09B1.35B1.06B530.7M513.4M392.3M843.2M700.4M236.3M337.3M230M180.8M192.5M506.8M180.9M
Cash at End11.95B8.71B8.88B8.53B13.3B12.69B11.04B8.41B4.29B1.9B3.52B2.46B2.48B4.09B1.38B1.41B1.43B1.09B1.35B1.06B530.7M513.4M392.3M843.2M700.4M236.3M337.3M230M180.8M192.5M0
Free Cash Flow15.57B7.81B6.33B10.39B13.45B15.74B13.43B10.39B6.83B6.09B7.92B6.17B6B3.8B4.64B3.98B2.77B1.49B1.77B1.42B-26.5M116.7M-433.5M-152.8M96M-33M84.9M3.6M-209.9M-447.4M-375.6M
FCF Growth %147.37%23.41%-39.14%-22.71%-14.58%17.26%29.23%52.18%12.14%-23.09%28.27%2.85%57.96%-18.14%16.49%43.62%86.55%-15.85%24.05%5475.09%-122.71%126.92%-183.7%-259.17%390.91%-138.87%2258.33%101.72%53.08%-19.12%-445.14%
FCF Margin %3.7%1.94%1.7%2.91%4.17%5.39%5%4.05%3.51%3.3%4.46%4.03%4.31%3%3.77%3.72%2.9%1.51%2.02%1.87%-0.06%0.32%-1.42%-0.57%0.4%-0.15%0.42%0.02%-1.37%-3.25%-3.17%
FCF per Share12.066.145.018.0610.1711.8510.227.966.545.957.345.485.133.13.632.962.011.031.21.04-0.030.14-0.53-0.190.12-0.040.110-0.26-0.57-0.88

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Regulatory scrutiny of vertical integration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Float Generation Turns Volatile Quarterly

Based on EDBL's reported figures, CVS operating cash flow ranged from a $745M outflow in 2024Q3 to $6.3B in 2026Q2, with OCF to net income ratios swinging between -8.56 and 2.56, suggesting underwriting float generation is uneven rather than structurally reliable.

The swing from negative operating cash in 2024Q3 to peak inflows in 2026Q2 indicates that premium collection timing and claims payment timing are not stable enough to treat the quarterly float as a dependable funding source. Claims and losses of roughly $78B to $94B per quarter dwarf the operating cash line, so modest timing shifts in medical cost payments can move OCF materially. Investors should monitor whether the recent run of OCF exceeding net income reflects genuine float expansion or temporary working capital timing.

Investment Portfolio Runs Net Liquidating

According to recent SEC filings, CVS sold or matured investments of $2.7B to $4.2B in most recent quarters against purchases of $3.9B to $5.9B, a pattern that suggests the portfolio has been a net cash user rather than a source of funding.

Purchases exceeding sales in most quarters point to ongoing reinvestment of float into the portfolio rather than liquidation to fund operations. The 2026Q1 period, where sales of $4.2B roughly matched purchases of $4.2B, appears to be the exception rather than a new trend. This pattern warrants further investigation into the yield profile of new allocations given the thin net margin of 0.44%.

Dividend Coverage Depends on Operating Cash

Based on reported figures, quarterly dividends of roughly $838M to $878M were paid consistently, while buybacks were negligible at under $3M, meaning capital returns rest almost entirely on operating cash generation.

The dividend has been held nearly flat across ten quarters despite volatile operating cash, which means the coverage ratio tightens sharply in quarters like 2025Q3 when OCF turned slightly negative at $796M. With a debt-to-equity ratio of 1.24 and a 2.3% ROE, the capacity to maintain the payout through a prolonged OCF shortfall appears limited. Investors should monitor whether the payout remains covered across full-year cash flow rather than individual quarters.

Net Income Volatility Versus Cash Reality

As reported in financial statements, CVS posted a $4.0B net loss in 2025Q3 while still generating $796M of operating cash, and then reported $2.2B net income in 2026Q3 alongside $4.7B of operating cash, a divergence that warrants scrutiny of accrual quality.

The gap between net income and operating cash in both directions suggests that reserve adjustments and non-cash charges are significantly shaping reported earnings. A large GAAP loss paired with positive operating cash implies the 2025Q3 loss was largely non-cash, consistent with reserve or impairment charges rather than cash deterioration. Conversely, the 2026Q3 profit may partly reflect favorable reserve development that does not indicate durable cash generation.

Cash Strength May Mask Reserve Risk

Based on EDBL's reported figures, CVS's strong 2026Q2 operating cash of $6.3B against $3.0B net income may overstate durable cash generation, since claims and losses of $90.3B that quarter could embed reserve timing effects not visible in the cash line.

A period of OCF running well above net income can reflect reserve builds or delayed claim payments rather than structural float expansion, which would reverse as claims settle. The cash flow statement alone does not reveal the adequacy of medical claims reserves or reinsurance recoverables, so the apparent cash strength should be treated as provisional. Investors should monitor whether subsequent quarters sustain OCF above net income once reserve development is isolated.

CVS — Frequently Asked Questions

Quick answers to the most common questions about buying CVS stock.

How much cash does CVS Health Corp. (CVS) generate from operations?

CVS Health Corp. (CVS) generated $10.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is CVS Health Corp.'s free cash flow?

CVS Health Corp. (CVS) generated $7.81B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is CVS Health Corp.'s capital expenditure (CapEx)?

CVS Health Corp. (CVS) spent $2.83B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does CVS Health Corp. distribute cash to shareholders?

In 2025, CVS Health Corp. (CVS) returned $3.40B to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.